| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 8.646 | 51.592 | 6.658 | 0 | 4.123 | 6.911 | 10.809 | 11.298 |
| Total Income - EUR | 0 | 0 | 23.259 | 51.640 | 6.670 | 6 | 4.123 | 6.911 | 10.809 | 11.298 |
| Total Expenses - EUR | 26.673 | 14.404 | 13.784 | 46.526 | 7.655 | 3.167 | 4.931 | 4.801 | 10.352 | 10.188 |
| Gross Profit/Loss - EUR | -26.673 | -14.404 | 9.475 | 5.114 | -985 | -3.161 | -807 | 2.110 | 457 | 1.111 |
| Net Profit/Loss - EUR | -26.673 | -14.404 | 7.757 | 3.566 | -1.185 | -3.161 | -849 | 1.919 | 349 | 933 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
Check the financial reports for the company - Vexmed Pharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 24.543 | 14.552 | 4.769 | -780 | -765 | -2 | 2.002 | 1.461 | 910 | 362 |
| Current Assets | 6.227 | 4.506 | 3.566 | 9.269 | 9.227 | 6.309 | 2.521 | 1.431 | 3.556 | 4.751 |
| Inventories | 0 | 0 | 0 | 2.714 | 2.661 | 0 | 263 | 264 | 322 | 59 |
| Receivables | 1.905 | 3.560 | 2.670 | 6.406 | 6.304 | 6.184 | 1.790 | 63 | 0 | 231 |
| Cash | 4.322 | 946 | 896 | 150 | 261 | 124 | 469 | 1.104 | 3.234 | 4.461 |
| Shareholders Funds | -26.628 | -40.715 | -32.269 | -28.112 | -28.751 | -31.367 | -31.520 | -29.699 | -29.260 | -28.163 |
| Social Capital | 45 | 89 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 57.398 | 59.773 | 40.604 | 36.600 | 37.213 | 37.674 | 36.044 | 32.590 | 33.726 | 33.277 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8129 - 8129" | |||||||||
| CAEN Financial Year |
145
|
|||||||||
Comments - Vexmed Pharm Srl